ELDRED KARY 4
4 · GALECTIN THERAPEUTICS INC · Filed Mar 29, 2021
Insider Transaction Report
Form 4
ELDRED KARY
Director
Transactions
- Award
Stock option (right to buy)
2021-03-25+40,000→ 40,000 totalExercise: $2.11Exp: 2031-03-25→ Common Stock (40,000 underlying) - Award
Stock option (right to buy)
2021-03-25+70,000→ 70,000 totalExercise: $2.11Exp: 2031-03-25→ Common Stock (70,000 underlying)
Footnotes (3)
- [F1]The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
- [F2]Such options vest 100% on March 31, 2022.
- [F3]Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results.